eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2022-06-30 15 2 831 836 10.13005/bpj/2419 44404 article Moushira Zaki 1 Mona Abd Elmotaleb A. Hussein 2 Hend M. Tawfeek 3 Nadia Mohamed Ahmed 4 Amr M M Ibrahim 4 Eman R. Youness 4 Biological Anthropology Department, National Research Centre, Giza, Egypt. Internal Medicine National Institute of Diabetes and Endocrinology, Cairo, Egypt. Internal Medicine Faculty of Medicine, Al-Azhar University- Girls. Medical Biochemistry Department, Medical Research Division, National Research Centre, Giza, Egypt We aimed to evaluate the levels of serum tissue inhibitor metalloproteinase-1 (TIMP-1) and matrix metalloproteinase-1 (MMP-1) in patients with type 2 diabetes (T2D)alone and in diabetic nephropathy(DN) and assess their relation with other clinical features. This study was conducted on 30 patients withT2D, 30 with diabetic nephropathy (DN) and 50 age- corresponded healthy individuals. Serum MMP-1 and TIMP-1 were measured with ELISA in patients and controls. Elevated serum concetrations of TIMP-1 and MMP-1 were recognized in DN group compared to patients with T2D alone as well as controls.  Positive correlation was also observed between MMP-1, TIMP-1, FBG and HbA1c in DN group. In multiple linear regression analysis HBLA1c, TG and low HDL were selected as components significantly related to MMP-1 and TIMP-1 in DN patients. in conclusion, serum MMP-1 and TIMP-1were significantly increased in DN. Further, in DM type 2 both markers were not significantly increased than controls. These blood biomarkers are associated with DN and might be salutary in clinical discrimination of DN in patients with type 2 diabetes. https://biomedpharmajournal.org/vol15no2/evaluation-of-serum-levels-of-tissue-inhibitor-metalloproteinase-1and-matrix-metalloproteinase-1-in-egyptian-patients-with-diabetic-nephropathy/ DN HbA1c  MMP-1   TIMP-1